Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.Omeros price target raised to $34 from $31 at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Omeros to $34 from $31 and keeps a Buy rating on the shares after the company announced that the Biologics License Application for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy has been accepted for filing by the FDA.Our Take: Looks positive and we see a lot of potential here. May not be the best time to start a new position as this jumped earlier this week. $OMER, Omeros Corporation / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .